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Abstract: (Pro)renin receptor (PRR) is a protein that takes part in several signaling pathways such as
Renin Angiotensin System and Wnt signalling. Its biological role has recently been related to cancer
progression and in this study, we investigated its relevance in colorectal cancer (CRC). To that end,
we analysed the immunohistochemical expression of PRR in adenomatous polyps and CRCs from
the same patients (n = 42), and in primary tumours and nodal and liver metastases from advanced
CRC patients (n = 294). In addition, the soluble fraction of PRR was measured by ELISA in plasma
samples from 161 CRC patients. The results showed that PRR expression was gradually augmented
along the uninvolved mucosa–adenoma–adenocarcinoma sequence. Besides, the stronger expression
of PRR in primary tumours was markedly associated with local tumour extent and the onset of
metastases. Moreover, PRR expression in both primary and distant metastases was associated with
worse 5- and 10-year survival of CRC patients. Plasmatic PRR levels did not change with respect to
controls and were not associated with CRC aggressiveness. These results suggest a key role of PRR
in the development and progression of CRC and a potential use of this protein as a new prognostic
biomarker and/or therapeutic target for this disease.
Keywords: (pro)renin receptor; adenoma; colorectal cancer; biomarkers; angiotensin; Wnt; vATPase
1. Introduction
Colorectal cancer (CRC) is one of the most common cancers worldwide, considerably increased in
Western countries for its association with sedentary lifestyles and bad diet habits [1]. Even if the lately
implemented screenings for its early detection have diminished the death rates, its high incidence
still makes it the second cause of cancer-related deaths [2]. Therefore, a better understanding of
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the biomolecular changes involving colorectal carcinogenesis is necessary for the design of effective
diagnostic, prognostic and therapeutic tools.
(Pro)renin receptor (PRR) was discovered in 2002 by Nguyen et al. [3]. It is a component of the
Renin Angiotensin System (RAS), an endocrine peptide system classically related to the regulation
of blood pressure and hydro-electrolytic balance [4]. The main physiological functions of RAS seem
to be transduced by the angiotensin II type 1 receptor (AT1R) pathway [5–13]. However, beyond
its classically known functions, RAS has been proved to be a complex system expressed in several
tissues whose bioactive peptides and receptors locally regulate processes such as cell growth and
proliferation too. In the last two decades, there has been an exponential increase in epidemiologic,
basic and translational research demonstrating that imbalances in RAS are associated with cancer
development and progression [7,14,15].
PRR is a protein able to bind renin enzyme and its inactive precursor prorenin, causing the
activation and increase in their activity. Active renin catalyses the conversion of angiotensinogen
into angiotensin I, contributing to the generation of angiotensin peptides that will further trigger the
consequent effects by its binding to their receptors [16,17]. Moreover, PRR also acts as a membrane
receptor which, after (pro)renin binding, is able to activate different intracellular secondary messengers
such as MAPK, ERK1/2, TGF-B, PLZF, PAI-1 or COX2 [3,18–22].
Besides, PRR has also been associated with the Wnt–β-catenin signalling pathway [23],
the activation of which is an initiating event of colorectal carcinogenesis [24,25]. Additionally, PRR has
been tightly linked to the vacuolar ATPase (vATPase). In fact, it is an accessory protein of the vATPase
that seems to be essential for its correct assembly [3,26]. vATPase activity has been linked to cancer,
as it is associated with compartment acidification and autophagy, among others functions [27].
Moreover, PRR can be found in different conformations: full-length or truncated. In fact, both furin
and ADAM19 enzymes are able to cleave PRR, generating a truncated membrane protein and a soluble
PRR (sPRR) [28–30]. The latter can be found in human fluids such as blood or urine, which could be
used as biomarker for detection or prognosis of different diseases [28].
Several preliminary studies suggest an important role of PRR in cancer cells, where this protein
has been found overexpressed [31–36]. Moreover, this overexpression is able to alter the hallmarks
of cancer described by Hannahan and Weinberg [37] by different mechanisms. In fact, PRR can
encourage proliferation and inhibit apoptosis by the activation of MAPK and PI3K/AKT intracellular
pathways [31,34]. Additionally, its tumorigenic role has been associated with the activation of
intracellular signalling stimulated by (pro)renin binding, as well as to vATPase and Wnt–β-catenin
signalling pathways [33,35,36]. Regarding the latter, a very recent study has demonstrated that PRR
can induce CRC progression by activating Wnt–β-catenin signalling, and proposed this protein as a
potential diagnostic and therapeutic target for this disease [38].
The objective of the present study was to analyse the expression of PRR in a series of CRC tissues
and plasma from CRC patients. For this purpose, we first studied the immunohistochemical expression
of PRR through the uninvolved mucosa-adenoma-CRC sequence from the same patients. In a second
step, we aimed to analyse PRR expression in the centre and the infiltrating front of primary tumours
but also in local lymph nodes and distant liver metastases from these primary tumours. For this reason,
advanced CRCs were mainly included in the study. Finally, the soluble fraction of PRR was analysed
in plasma samples from CRC patients.
2. Results
2.1. Patients Clinical and Pathological Parameters
A set of 42 prospectively collected samples of CRC patients was employed to analyse the polyp-cancer
sequence, where each case includes a tissue fraction of the three different phases of the polyp-cancer
sequence: uninvolved mucosa, adenomatous polyp and cancer tissue. Males predominated in the series
(34M/8F), with an average age of 68 years old.
Cancers 2019, 11, 881 3 of 18
Additionally, we also employed a tissue collection that comprises a batch of retrospectively
collected tissues from 294 advanced CRC patients with long follow-up. The collection included a
tissue fraction of four different anatomic locations that represent the progression of CRC: the centre
and the infiltrating front of the primary tumour, which were obtained in all the cases; tissues from local
lymph node metastases, which were obtained in 232 cases; and liver metastases, obtained in 123 cases.
The detailed information of the sample collection is described in Table 1.
Table 1. Clinical and pathological parameters of the colorectal cancer (CRC) patients’ tissues used for
(pro)renin receptor (PRR) immunohistochemical analysis.
Patients’ Clinical and Pathological Data (n = 294) Average (%)
Age average (range) 70 (29–93)
Follow-up months (range) 44 (0–188)
Gender
Male 203 (69%)
Female 91 (31%)
Histologic subtype
Intestinal-type Adenocarcinoma (AdC) 231 (79%)
Mucinous carcinoma (MuC) 50 (17%)
Signet ring cell carcinoma (SrcC) 13 (4%)
Histologic grade (G)
G1 37 (13%)
G2 161 (55%)
G3 95 (32%)
Local invasion (pT)
pT1 2 (<1%)
pT2 13 (4%)
pT3 178 (61%)
pT4 101 (34%)
Affected lymph nodes (N)
N0 37 (13%)
N1 161 (55%)
N2 95 (32%)
Distant metastases (M) M0 182 (62%)
M1 112 (38%)
Stage (TNM system) *
I 7 (2%)
II 25 (9%)
III 150 (51%)
IV 112 (38%)
* American Joint Committee on Cancer. 7th edition.
2.2. PRR Protein Expression in Human Colonic Tissues
2.2.1. PRR Expression According to the Gender and Age of the CRC Patients
Rho Spearman tests did not show any statistically significant correlations between gender or age
and PRR protein expression levels (p > 0.05), which permits an unbiased study of all the cases with
neither age nor gender distinction.
2.2.2. PRR Expression along the Polyp-Cancer Sequence
The results disclosed that PRR is gradually augmented along the polyp-cancer sequence. In fact,
PRR is absent in normal colonic tissues, while its expression rises in adenomatous polyps and
strongly increases in CRC tissues (Figure 1). This gradual increase in PRR staining intensity along
the polyp-cancer sequence was statistically significant when comparing the three phases among them
separately (Chi square p < 0.00001).
2.2.3. PRR Expression According to the Histologic Subtype
We found significant PRR expression differences according to the histologic subtype. Intestinal-type
adenocarcinomas (AdCs) showed significant stronger PRR expression than mucinous (MuCs) and
signet ring cell carcinomas (SrcCs) (Table 2).
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Figure 1. Immunohistochemical PRR staining along the adenomatous polyp-cancer sequence of CRC. 
(a) Representative fractions of uninvolved colonic mucosa, polyp and cancer tissue of 42 CRC patients 
were immunohistochemically stained with an antibody against PRR. Granular cytoplasmic staining 
was observed in neoplastic cells (black arrowhead). Stromal cellularity (lymphocytes and fibroblasts) 
did not express PRR (red asterisk). (b) PRR staining intensity was scored as negative, moderate or 
strong. The scores were quantified in each tissue type and statistical significance of the PRR intensity 
pattern among the different tissues was determined by Chi-Square test. H&E: Hematoxylin and Eosin 
staining. PRR: (pro)renin receptor staining. 
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type adenocarcinomas (AdCs) showed significant stronger PRR expression than mucinous (MuCs) 
and signet ring cell carcinomas (SrcCs) (Table 2).  
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fractions of intestinal-type, mucinous and signet ring cell carcinomas were immunohistochemically 
stained in the centre of the tumour, tumour front, local metastasis and distant metastasis. PRR staining 
intensity was scored as negative, moderate or strong. The scores were quantified in each histologic 
subtype and statistical significance was determined by Chi-Square test. 
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Signet ring cell carcinoma (SrcC) 0.0 81.8 18.2 
Local metastasis 
Adenocarcinoma (AdC) 2.8 52.3 44.9 
0.024 c Mucinous carcinoma (MuC) 11.1 55.6 33.3 
Signet ring cell carcinoma (SrcC) 0.0 84.6 15.4 
Distant metastasis 
Adenocarcinoma (AdC) 7.4 39.4 53.2 
0.003 d Mucinous carcinoma (MuC) 15.8 73.7 10.5 
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Figure 1. I unohistoche ical P staining along the adeno atous polyp-cancer sequence of .
(a) Representative fractions of uninvolved colonic ucosa, polyp and cancer tissue of 42 CRC patients
ere i unohistoche ically stained ith an antibody against PRR. Granular cytoplas ic staining
as observed in neoplastic cells (black arro head). Stro al cellularity (ly phocytes and fibroblasts)
did not express PRR (red asterisk). (b) PRR staining intensity was scored as negative, oderate or
strong. The scores were quantified in each tissue type and statistical significance of the PRR intensity
pattern among the different tissues was determined by Chi-Square test. H&E: Hematoxylin and Eosin
staining. PRR: (pro)renin receptor staining.
Table 2. Immunohistochemical PRR staining according to CRC histologic subtypes. Representative
fractions of intestinal-type, mucinous and signet ring cell carcinomas were immunohistochemically
stained in the centre of the tumour, tumour front, local metastasis and distant metastasis. PRR staining
intensity was scored as negative, moderate or strong. The scores were quantified in each histologic
subtype and statistical significance was determined by Chi-Square test.
Heading NegativeStaining (%)
Moderate
Staining (%)
Strong
Staining (%)
Chi-square
(p valu )
Tumour centre
Adenocarcinoma (AdC) 2.2 39.0 58.8
9 × 10−6 aMucinous carcinoma (MuC) 4.1 75.5 20.4
Signet ring cell carcinoma (SrcC) 0.0 76.9 23.1
Tumour front
Adenocarcinoma (AdC) 0.9 37.4 61.7
0.001 bMucinous carcinoma (MuC) 4.4 60.0 35.6
Signet ring cell carcinoma (SrcC) 0.0 81.8 18.2
Local
metastasis
Adenocarcinoma (AdC) 2.8 52.3 44.9
0.024 cMucinous carcinoma (MuC) 11.1 55.6 33.3
Signet ring cell carcinoma (SrcC) 0.0 84.6 15.4
Distant
metastasis
Adenocarcinoma (AdC) 7.4 39.4 53.2
0.003 dMucinous carcinoma (MuC) 15.8 73.7 10.5
Signet ring cell carcinoma (SrcC) 28.6 57.1 14.3
a: Statistical significance was reached between AdCs and MuCs (p = 7 × 10−6) and AdCs and SrcCs (p = 0.025).
b: Statistical significance was reached between AdCs and MuCs (p = 0.002) and AdCs and SrcCs (p = 0.013).
c: Statistical significance was reached between AdCs and MuCs (p = 0.05). d: Statistical significance was reached
between AdCs and MuCs (p = 0.003).
To avoid histologic subtype-related bias, all the subsequent studies were conducted taking into
consideration only AdCs, as they confor the great majority of all the cases.
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2.2.4. PRR Expression along the Conversion of the Primary Tumour into Metastasis
PRR staining was analysed along the progression of CRC, measuring its expression in four
different locations: the centre of the primary tumour, the infiltrating front of the primary tumour,
lymph node local metastasis and distant metastasis to liver (Figure 2a). The results showed that PRR is
similarly expressed in both the centre and the infiltrating front of the primary tumour (Chi square
p > 0.05), prevailing strong staining in 60% of the cases. On the other hand, both the centre and the
front of the primary tumours presented stronger PRR staining than the metastatic tissues. Specifically,
while PRR expression in the tumour centre was significantly stronger than the tissues obtained from
local metastases (Chi square p = 0.021), PRR was significantly higher in the infiltrating front than in
both local (Chi square p = 0.002) and distant metastases (Chi square p = 0.004) (Figure 2b).
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Figure 2. I ist c e ic l st i i l t e c ersi f t e pri ar tu o r into
etastasis. (a) e resentative fractions of the centre of the pri ary tumour (n = 228), i filtrating front
of the pri ary tu our (n = 222), local ly ph node etastasis (n = 176) and distant etastasis (n = 94)
ere im unohistoche ically stained ith an antibody against PRR. Granular cytoplas ic staining
as observed in neoplastic cells (black arro head). Stro al cellularity (ly phocytes and fibroblasts)
did not express PRR (red asterisk). (b) PRR staining intensity as scored as negative, oderate or
strong. The scores were quantified in each tissue type and statistical significance of the PRR intensity
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staining. PRR: (pro)renin receptor staining.
2.2.5. PRR Expression According to CRC Aggressiveness
In order to investigate whether PRR protein expression was able to predict CRC prognosis,
we stratified PRR protein expression according to several clinical parameters, such as histological
grade, local invasion (pT), number of affected lymph nodes (N), presence/absence of metastasis (M)
and the stage (TNM system) (Table 3).
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Table 3. PRR protein expression levels according to the different pathological parameters in the centre
and the infiltrating front of the analysed primary tumours.
Tumour Centre Tumour Front
Negative
Staining
(%)
Moderate
Staining
(%)
Strong
Staining
(%)
Chi-square
(p value)
Negative
Staining
(%)
Moderate
Staining
(%)
Strong
Staining
(%)
Chi-square
(p value)
Grade
1 2.8 41.7 55.6
0.55
0 37.5 62.5
0.2702 1.3 39.2 59.5 0.6 34.6 64.7
3 5.9 35.3 58.8 2.9 50 47.1
pT
pT1–pT2 0 64.3 35.7
0.001 a
0 71.4 28.6
0.051 bpT3 0.7 44.7 54.7 1.4 37.2 61.4
pT4 6.3 20.3 73.4 0 30.2 69.8
N
N0 2.7 48.6 48.6
0.038 c
2.8 41.7 55.6
0.564N1 0 43.5 56.5 0.9 37.7 61.3
N2 4.8 28.9 66.3 0 35 65
M
M0 3 47.8 49.3
0.002
0 45.4 54.6
0.005
M1 1.1 26.6 72.3 2.2 26.1 71.7
Stage
I-II 4.2 62.5 33.3
0.004 d
0 52.2 47.8
0.023 eIII 2.7 44.5 52.7 0 43.9 56.1
IV 1.1 26.6 72.3 2.2 26.1 71.7
a: Statistical significance was reached between samples belonging to pT1–T2 and pT4 (p = 0.004), and pT3 and
pT4 (p = 3.8 × 10−4). b: Statistical significance was reached between pT1–T2 and pT3 (p = 0.044), and pT1–T2 and
pT4 (p = 0.004). c: Statistical significance was reached between samples from N1 and N2 (p = 0.01). d: Statistical
significance was reached between samples corresponding to stages I–II and IV (p = 0.002), and stages III and IV
(p = 0.015). e: Statistical significance was reached between stages I–II and IV (p = 0.048), and stages III and IV
(p = 0.013).
PRR expression was stronger in tumours that presented greater invasion throughout the wall of the
colon or rectum. In the tumour centre, the PRR expression of AdCs that invaded visceral peritoneum or
other adjacent organs (pT4) was significantly stronger than in tumours invading muscularis propria into
the pericolorectal tissues (pT3) and tumours invading submucosa and muscularis propria (pT1–pT2).
Differences were also found between pT3 and pT1–pT2 tumours. In the tumour front, pT4 and pT3
tumours showed significantly stronger PRR expression than pT1–pT2.
On the other hand, PRR staining in the tumour centre was stronger in cases corresponding to N2
(metastases in four or more regional lymph nodes) compared to those belonging to N1 (metastases in
1–3 regional lymph nodes).
In addition, PRR protein expression in primary tumours showed higher staining intensity in cases
with distant metastasis at diagnosis time (M1) than those belonging to M0. It is important to note that
PRR expression in lymph nodes was also stronger in the AdCs that presented distant metastases at
diagnosis time (M0 vs M1, Chi-square p = 0.048).
Finally, PRR expression was stratified according to TNM stage. Since this series was mainly
composed of advanced CRCs, stage I and II (not advanced) were grouped in a single group (stage
I–II), and were compared with advanced tumours, stage III (those who had invaded lymph nodes)
and IV (those who had invaded distant organs). The results showed that PRR expression in primary
tumours gradually increased from low to advanced stages. Statistically significant differences were
found between stage I–II and stage IV, and among stage III and IV.
No significant differences of PRR protein expression were found among samples corresponding
to different histologic grades.
Following previously reported classifications [39], distant metastases were classified as
synchronous when they were detected within the first six months from diagnosis time (n = 88).
Those AdCs that debuted after 6 months from initial diagnosis were categorized as metachronous
(n = 143). The results showed that PRR expression in both primary tumours’ centre and infiltrating
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front was significantly higher in patients with synchronous metastases compared to the ones with
metachronous ones (Chi-square p < 0.05) (Figure 3).
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Figure 3. PRR protein expression according to the metastatic relapse time of CRC patients. PRR staining
intensity was scored as negative, moderate or strong. The scores were quantified in each tissue group
and statistical significance of the PRR intensity pattern among the different tissues was determined by
Chi-Square test. (*) p < 0.05.
2.2.6. PRR Expression According to the Overall Survival of CRC Patients
The PRR immunostaining patterns observed in the tumour centre, infiltrating front, local metastasis
and distant metastasis were stratified according to patients’ 5- and 10-year overall survival (OS).
The average follow-up of the AdC series (n = 231) was 45.01 months ranging from 0 to 184 months.
Representative 60-months overall survival Kaplan–Meier curves are presented in Figure 4. In addition,
120-months overall survival curves were also performed (Supplementary Figure S1). Statistical
significance at both 60- and 120-months follow-up are gathered in Table 4.
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Figure 4. Overall survival of CRC patients according to PRR staining. Tissues scored as negative
were not included in the study for conforming groups with insufficient number of cases. Survival
Kaplan–Meier curves were generated along 5 years (60-months) follow-up, comparing moderate and
strong PRR staining in CRC tissues belonging to the centre, infiltrating front, local metastasis and
distant metastasis.
Cancers 2019, 11, 881 8 of 18
Table 4. Log-rank test results of the association between PRR expression in primary tumours and
metastases and 5- and 10-year overall survival of CRC patients.
PRR Protein
Expression Cut-off Follow-up Time n (%) Log-Rank (p value)
Tumour centre
Moderate
staining/Strong
staining
60 months Alive 58 (26%)Dead 165 (74%) 0.013
120 months Alive 15 (7%)Dead 208 (93%) 0.038
Tumour front
Moderate
staining/Strong
staining
60 months Alive 58 (26%)Dead 162 (74%) 0.051
120 months Alive 15 (7%)Dead 205 (93%) 0.062
Local metastasis
Moderate
staining/Strong
staining
60 months Alive 41 (24%)Dead 130 (76%) 0.029
120 months Alive 14 (8%)Dead 157 (92%) 0.038
Distant metastasis
Moderate
staining/Strong
staining
60 months Alive 21 (24%)Dead 66 (76%) 0.019
120 months Alive 3 (3%)Dead 84 (97%) 0.037
The results showed that patients with stronger PRR protein expression in CRC tissues had worse
5- and 10-year overall survival than patients with moderate PRR expression. These results were
statistically significant in the tumour centre and local and distant metastases for 5- and 10-year overall
survival (Table 4).
With the aim to investigate whether PRR protein expression was an independent factor to predict
CRC patients’ OS, univariate and multivariate analyses were conducted, considering several clinical
and pathological variables and PRR expression. All the parameters presented statistical significance
with 5-year OS (p < 0.05) in the univariate analysis, except for PRR protein expression in the infiltrating
front of the primary tumour (p > 0.05) (Supplementary Table S1). All those parameters that correlated
with OS in the univariate analysis were included in the Cox regression multivariate analyses (Table 5).
The results indicated that PRR is not an independent prognosis factor for the prediction of CRC patients’
overall survival in none of the locations and that metastases were the main independent prognostic
factor influencing 5-year survival. The same uni- and multivariate analyses were conducted at 10-year
overall survival, from which similar results were obtained (Supplementary Tables S2 and S3).
Table 5. Multivariate analysis (Cox regression model) of clinical and pathological variables and PRR
expression in the centre of primary tumours and local and distant metastases for CRC patients’ overall
survival prediction. Odds ratios (ORs) and inferior and superior confidence intervals (CIs) are also
included. A 95% CI for OR was considered. Statistically significant values are highlighted in bold.
Variables Grade pT N M PRR
Tumour
Centre
p value 0.032 3.9 × 10−4 0.777 6.4 × 10−5 0.599
OR 1.376 1.728 1.035 1.915 1.095
Inferior 1.028 1.277 0.818 1.392 0.780
Superior 1.841 2.337 1.308 2.633 1.537
Local
Metastasis
p value 0.087 0.002 0.903 2.6 × 10−4 0.089
OR 1.334 1.689 0.980 1.939 1.358
Inferior 0.959 1.214 0.703 1.359 0.954
Superior 1.855 2.351 1.365 2.768 1.933
Distant
Metastasis
p value 0.708 0.400 0.098 0.021 0.058
OR 1.091 1.214 1.344 1.888 1.683
Inferior 0.692 0.772 0.947 1.100 0.982
Superior 1.720 1.909 1.909 3.242 2.882
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We also performed a multiple logistic regression analysis to demonstrate which variable between
histologic grade (G), local invasion (pT), node invasion (N) and PRR protein expression was the main
factor influencing the onset of metastases. The results revealed that the most significant variable
was PRR expression in the centre of the tumour (p < 0.01) and in the infiltrating front (p < 0.05).
Local invasion (pT) was also included in the final step of the backward Wald method in the centre of
the tumour, although it did not reach statistical significance (Table 6).
Table 6. Multiple logistic regression model for the prediction of metastasis presence in CRC patients
at diagnosis time. A stepwise selection procedure (backward Wald method) was used to select the
final optimal model. Odds ratios (ORs) and inferior and superior confidence intervals (CIs) are also
included. According to the Omnibus test, the model was statistically significant (p < 0.001 in the centre
and p < 0.01 in the infiltrating front). Hosmer–Lemershow test p = 0.88 in the centre and p = 0.81 in
the front). R2 Nagelkerke 0.1 in the centre and 0.08 in the front. A 95% CI for OR was considered.
Statistically significant values are highlighted in bold.
Multiple Logistic Regresssion Final Step of the Wald Method
Variables Grade pT N PRR PRR pT
Tumour
centre
p value 0.55 0.09 0.58 0.003 0.002 0.09
B 0.24 1.36 0.25 0.87 0.92 1.35
OR 1.28 3.9 1.28 2.39 2.5 3.85
Inferior 0.57 0.78 0.53 1.33 1.4 0.82
Superior 2.8 19.3 3.1 4.3 4.46 18.03
Tumour
front
p value 0.69 0.15 0.45 0.01 0.005 -
B 0.16 1.17 0.34 0.76 0.83 -
OR 1.18 3.23 1.41 2.14 2.28 -
Inferior 0.53 0.66 0.58 1.18 1.28 -
Superior 2.61 15.8 3.43 3.89 4.08 -
2.2.7. PRR Expression According to Disease-Free Survival of CRC Patients
PRR expression was also stratified depending on the disease-free survival (DFS) of the patients.
There was not any association between PRR expression in primary tumours and 5- and 10-year DFS
(Supplementary Table S4).
2.2.8. PRR Expression According to the Tumour Budding
With the objective to evaluate whether PRR protein expression bears any association with tumour
budding, two parameters were evaluated by H&E staining: on the one hand, poorly differentiated
clusters (PDCs) were evaluated. To that end, the number of the poorly differentiated clusters comprising
≥5 cancer cells were quantified (Supplementary Figure S2A). On the other hand, the desmoplastic
response (DR) was assessed by classifying stroma as mature, intermediate (keloid-like collagen) or
immature (myxoid stroma) (Supplementary Figure S2B). Those two parameters were then correlated
with the PRR staining intensity found in the primary tumour.
The results showed no statistical significance in the correlation between CRC primary tumour
PRR staining and PDC (Chi square test p > 0.05) and neither with DR (Chi square test p > 0.05)
(Supplementary Table S5).
2.3. Soluble PRR Concentration According to CRC Aggressiveness and Patients Survival
Soluble PRR plasma concentrations were measured in the plasma of 144 CRC patients. The clinical
and pathological parameters of the patients are gathered in Table 7. The plasma of 33 healthy controls
were also employed, composed of 21 males and 12 females, with an average age of 57 years old
(ranging from 49 to 64). Soluble PRR plasma levels follow normal distribution as proved by the
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Kolmogorov–Smirnov test (p < 0.05) and there were no sex or gender skew affecting PRR plasma levels
(Rho Spearman p > 0.05).
Table 7. Clinical and pathological parameters of the CRC patients used for soluble PRR analysis and
the p values obtained from the correlation of soluble PRR plasma levels and CRC patients’ clinical data.
Patients’ Clinical and Pathological Sata (n = 161) Average (%) sPRR Levels(ng/mL) p value
Follow-up months (range) 50 (3–84)
Age average (range) 70 (34–93)
Gender
Male 103 (72%)
Female 41 (28%)
Histologic subtype
Intestinal-type
adenocarcinoma (AdC) 128 (89%) 21.12 0.331
Mucinous carcinoma (MuC) 16 (11%) 20.22
Histologic grade (G)
G1 6 (4%) 19.49
0.676G2 119 (83%) 21.16
G3 19 (13%) 20.60
Local invasion (pT)
pT2 36 (25%) 20.59
0.561pT3 94 (65%) 20.99
pT4 14 (10%) 22.29
Affected lymph nodes (N)
N0 82 (57%) 21.25
N1 48 (33%) 20.61 0.781
N2 14 (10%) 21.07
Stage (TNM system)
I 28 (19%) 20.69
II 53 (37%) 21.35
III 59 (41%) 21.18 0.296
IV 4 (3%) 16.49
Statistical correlations were carried out to determine whether there is any association between
soluble PRR levels and CRC aggressiveness or outcome. The results showed no association between
PRR plasma concentration and histological grade, pT, N, M and stage (Table 7). Healthy controls
and CRC patients also showed similar sPRR plasma levels with no statistically significant differences
between them (T student test p > 0.05) (Figure 5a).
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low sPRR levels (cut-off point at 20.7 ng/mL) (Log-rank test p = 0.271).
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Patients with plasma samples presenting higher PRR levels tended to have a worse 5-year overall
survival than those with lower PRR (cut-off point set at the median: 20.7 ng/mL). However, this trend
did not reach statistical significance (Log-rank test p = 0.271) (Figure 5b)
3. Discussion
CRC is the consequence of several genetic and epigenetic alterations that promote gradual phenotypic
changes throughout the colonic normal mucosa–adenoma–adenocarcinoma sequence [40–42]. Numerous
proteins and signalling pathways that change along this sequence have already been identified
and have been useful for the pursuit of new diagnosis/prognosis biomarkers and therapies for this
disease [40,43]. Despite new molecular classifications, the treatment and prognosis of CRC patients
have been unchanged during the last 20 years. However, a large number of proteomic changes still
need to be elucidated for a better understanding of the behaviour of CRC and for new biomarkers and
therapeutic targets identification [43].
PRR is a novel RAS receptor, the involvement of which in cancer development and progression
has been under study during the last years [31–36]. Studies in different malignant tumours report
the existence of PRR overexpression in cancer cells compared to non-tumoural ones. In agreement
with these results, a very recent study showed a higher PRR expression in CRC cells than in normal
colonic mucosa [38]. This prominent study disclosed the need for additional thorough studies that
may fully elucidate the role of PRR in CRC. In this line, our study contributes to the current literature
by including adenomatous precursors for a novel complete description of PRR throughout normal
mucosa-adenoma-carcinoma sequence of the CRC patients. The analyses showed a gradual increase
in PRR staining intensity along the sequence, which was mainly negative in the uninvolved mucosa,
mostly moderate in adenomatous polyps and predominantly strong in CRC. These results reveal
the idea of a potential role of this protein in the initiation and progression of CRC by the gradual
acquisition of proliferative and malignant characteristics of tumour cells [38] throughout this multistep
model of colorectal carcinogenesis.
This finding led us to the second objective of the study, which was to analyse PRR expression in
both primary and metastatic tissues from advanced CRC patients. Thus, the second relevant result
of the study was that PRR expression changed according to the histologic subtype: mucinous and
signet ring cell carcinoma showed moderate PRR expression, while intestinal-type adenocarcinomas
(AdC) showed predominantly stronger intensity. The first two histotypes possess a greater mucus
proportion in the cell, making the dimensions of the cytoplasm smaller [44,45]. Considering that PRR
staining is cytoplasmic, we hypothesize that this fact may hinder the evaluation of the staining pattern,
making a hypothetical strong staining look weaker. Although this question requires further studies,
we strongly suggest that these histotype-related differences in the staining pattern should be taken into
consideration for the immunohistochemical evaluation of PRR in CRC tissues.
Since TNM is the gold standard for the stratification of CRC patients into prognostic subgroups [44],
we analysed whether local tumour extent (pT), invasion of regional nodes (N), metastasis occurrence (M)
and TNM stage were associated with PRR expression in AdC, the most frequent CRC [44]. In primary
tumours, the staining intensity of this protein gradually increased as tumour invades large intestine
wall and lymph nodes. Moreover, PRR expression was significantly associated with the onset of
synchronous metastases. As a consequence, stronger PRR expression was observed in cases belonging
to stage IV compared to those corresponding to lower stages.
A very recent study, performed in 60 CRC primary tumours, showed similar association between
PRR expression levels and tumour stage and patients’ 5-year survival [38]. Our data from a series of
231 AdC patients, that includes not only the centre and the front of primary tumours but also fractions
from local and distant metastases, further support these results and reveal new information. On the
one hand, strong PRR expression in primary tumours but also in metastasic tissues was associated with
lower 5- and 10-year survival of CRC patients. On the other hand, multivariate analyses revealed that
metastasis occurrence (M) was the most significant explanatory variable predicting survival. Besides,
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PRR was the most significant variable influencing metastasic onset compared to pT, pN and histologic
grade. Therefore, it could be suggested that the effect of PRR expression in patients’ survival could be
due to its influence on the metastasis.
Connected to this, intriguingly, we observed the loss of PRR expression in local and distant
metastases compared to the primary tumours, which could suggest that although PRR seems to have
an important role in the development of metastases, once it is generated, the adaptation of CRC cells
in the new microenvironment might prioritise alternative signalling pathways beyond PRR-related
ones (Malladi et al., 2016). Nevertheless, importantly, the expression of PRR in lymph nodes was
still associated with the onset of distant metastases and a stronger expression of PRR in both nodal
and hepatic metastases was correlated with lower survival of CRC patients, which suggests that the
role of PRR in metastases is also related to CRC aggressiveness. The use of in vivo models in future
studies and its relationship with new molecular subtypes might help clarify the specific role of PRR in
metastasis occurrence, since there is no background in the literature describing it [31–36].
Recently, tumour border configuration and tumour budding have been proposed as important
histomorphological variables for CRC prognosis [46,47]. The main difference between the centre and
the front of the primary tumour seems to be the increased infiltrating capacity of the cells located in
the tumour front [46]. Related to this, tumour budding has been defined as single cells or clusters of
up to four cells with morphologic manifestations of epithelial to mesenchymal transition (EMT) at
the invasive margin of CRC [47]. In this study, PRR expression was analysed in the centre and in the
infiltrative front of primary tumours but we did not find any significant difference between the two
locations. We neither found any correlation between PRR and the number of poorly differentiated
clusters (PDC) infiltrating the tumour stroma. These results might indirectly suggest that PRR does
not have a specific role in the achievement of the infiltrating capacity of CRC cells in the tumour front.
However, the fact that PRR shows no heterogeneity between the centre and tumour front of the primary
tumour should play in favour of a potential use of PRR as an immunohistochemical biomarker.
Thus, taken together, these results suggest a key role of PRR in CRC development and progression.
The interesting study of Wang et al. demonstrated that PRR regulates proliferation and apoptosis of
CRC cells in vitro and tumour growth in CRC xenografts in vivo. PRR regulated these hallmarks of
cancer through Wnt–β-catenin dependent mechanisms, which is a widely recognized pathway in the
initiation of CRC carcinogenesis [40].
However, although this mechanism is independent of RAS, a potential role of PRR in CRC in
the context of this peptidergic system should not be ruled out. Thus, recent findings demonstrated
that angiotensin-converting enzyme (ACE) and AT1R, which are the better known components and
drug-targets of RAS, significantly altered their expression and activity in CRC tissues when compared
to the uninvolved colorectal mucosa, and these changes were associated with CRC progression [48,49].
Our studies also demonstrated that imbalances of angiotensin receptors and angiotensin-regulating
peptidases were associated with CRC development and patients’ survival [50–52]. These findings
could explain in part the results of retrospective studies that show a protective role of RAS inhibitors in
the onset of CRC [14,15,53] but also in survival rates of metastatic CRC patients [54] and have opened
new perspectives in the study of colorectal carcinogenetic processes [15].
In addition to the use of PRR as a tissue biomarker for CRC detection and prognosis, we aimed
to complementarily measure it in CRC patients’ plasma samples to explore its potential as a CRC
biomarker in liquid biopsies. In fact, PRR is a membrane protein expressed in several tissues that,
after cleavage, can be released to the extracellular space and can be detected in plasma and urine
from subjects with different physiological and pathological conditions [28,30,55,56]. Shibayama et al.
recently reported higher sPRR levels in patients with pancreatic ductal adenocarcinoma than in healthy
controls [36]. However, our results in CRC patients’ plasma samples showed no statistically significant
differences compared to healthy controls. We did not find any association between sPRR levels and
aggressiveness-related parameters.
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These divergent results between solid and liquid biopsies are, however, recurrent in different
studies [57,58]. For instance, in previous works, we found similar discrepancies between the expression
of RAS components in tumour tissues and plasmas from CRC patients, but also detected no differences
when plasma from these patients was compared to matched controls [50,51,59]. Furthermore,
we conducted a similar study in samples of renal cancer patients and observed distinct results
compared to CRC, concluding that changes in tumour tissue and its reflection in plasma are cancer
type-dependent [60]. Therefore, further studies are necessary to understand the underlying mechanisms
that might create such divergences between tissue and plasma PRR expression in CRC patients.
Taken together, these results stress the potentiality of PRR as a CRC diagnostic/prognostic
biomarker and therapeutic target based on its aggressiveness–related protein expression in human
CRC tissues.
4. Materials and Methods
The authors declare that all the experiments carried out in this study comply with the current
Spanish and European Union legal regulations. Samples and data from patients included in this study
were provided by the Basque Biobank for Research-OEHUN (www.biobancovasco.org). All patients
were informed about the potential use for research of their surgically resected tissues and accepted this
eventuality by signing a specific document approved by the Ethical and Scientific Committees of the
Basque Country Public Health System (Osakidetza, Basque Country, Spain) (CEIC 11/51 and CEIC 18/37).
4.1. Immunohistochemistry
Formalin-fixed and paraffin-embedded tissues were immunostained with a rabbit polyclonal antibody
specific for PRR (HPA003156; Sigma-Aldrich, St. Louis, USA) at 1/50 dilution. (https://atlasantibodies.com/
products/ATP6AP2-antibody-HPA003156). The antibody’s specificity was previously tested by Western blot
and immunofluorescence techniques in PRR knocked down HCT116 and SW480 cell lines (Supplementary
Figure S3).
The immunostaining process was performed following routine methods in an automatic
immunostainer (Dako Autostainer Plus, Dako-Agilent, Santa Barbara, USA). Briefly, antigen retrieval
was carried out in a low pH buffer (K8005, Dako, Santa Barbara, USA) for 20 min at 95 ◦C. The samples
were incubated with the primary antibody for 50 min at room temperature. Then, the primary antibody
was washed, and samples were incubated for 20 min with secondary anti-rabbit antibody (K8021, Dako,
Santa Barbara, USA). The EnVision-Flex detection system together with a HRP (horseradish peroxidise)
enzyme-labelled polymer (SM802, Dako, Santa Barbara, USA) was employed. A positive reaction was
visualized with diaminobenzydine (DAB) solution (DM827, Dako) followed by counterstaining with
haematoxylin (K8008, Dako, Santa Barbara, USA).
For the staining evaluation, slides were reviewed under light microscopy. A weak granular cytoplasmic
staining in the epithelial cells of renal tubules was used as external control [61]. This staining pattern was
followed to score large bowel mucosa’s epithelial cell staining into negative, weak and strong.
The study of the epithelial–mesenchymal programme was made based on two histological settings.
Firstly, Poorly Differentiated Clusters (PDCs) were counted, which conforms a tumour budding
analogous quantification system [62,63]. For that purpose, ≥5 epithelial no gland-forming cell nests
located in the tumour front were identified. After selecting the highest PDC counting area, a three-grade
scoring system was followed, considering the following three groups: <5 (G1), 5–9 (G2) and ≥10 (G3)
PDCs. Additionally, we analysed the stromal collagen appearance of the entire tumour, discerning
three stromal desmoplastic patterns (Desmoplastic Response or DR): when multi-layered fine collagen
fibres were noted, the stroma was considered mature; eosinophilic broad bands of collagen were
described as keloid or intermediate stroma; abundant basophilic amorphous stroma was considered
myxoid or immature. In all cases, the most immature grade of stroma was considered for statistical
analysis [64].
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The specimens were independently evaluated by two observers and discordant cases were jointly
reviewed followed by a conclusive judgment.
4.2. ELISA Assays
In order to determine the levels of soluble PRR, a soluble (pro)renin receptor assay kit (27782; IBL)
was used [55]. A volume of 100 ul of standards, reagent blank and plasma samples (1/10 dilution) were
plated into a 96-well plate and incubated overnight at 4 ◦C. Wells were washed 4 times and 100 ul of
labelled PRR antibody was added (except to the blank) and incubated for 1 h at 4 ◦C. Then, wells were
washed 5 times and 100 uL of chromogen was added and incubated for 30 min at room temperature.
A volume of 100 uL of stop solution was added to each well and the absorbance was measured at
450 nm against reagent blank.
4.3. Statistical Analysis
SPSS® 24.0 software was used for the statistical analysis.
A Kolmogorov–Smirnov test was applied to data obtained from tissue and plasma samples to
determine whether the numbers followed a normal distribution. Based on this information, data were
analysed with parametric or non-parametric tests. We performed Pearson and Rho Spearman tests to
evaluate the correlation between PRR expression and patient age and gender. T-Student and Mann–Whitney
U tests (Mann-U) were used to compare tissue and plasmatic PRR levels between two groups and ANOVA
and Kruskal–Wallis tests were applied to detect differences between more than two groups.
Chi-square (χ2) test was used to analyse the categorical PRR expression throughout the
adenoma–CRC sequence, and the association with tissue PRR expression depending on pathological
CRC variables.
Finally, Kaplan–Meier curves and a log-rank test were performed to evaluate the association
between the expression of tissue PRR and plasmatic PRR levels and overall survival of CRC patients.
Groups were created by cut-off points based on categorical PRR expression in tissue (moderate/strong)
and plasma (lower/higher than median values). Multivariate analyses were used to test the independent
effects of PRR expression and clinical and pathological variables on survival (Cox regression model)
and in the onset of metastasis (multiple logistic regression).
5. Conclusions
The most relevant and novel findings of this study were that: (1) PRR expression gradually
increases throughout the uninvolved mucosa–adenoma–CRC sequence. (2) Strong PRR expression in
primary CRC tumours (AdCs) is associated with local tumour extent, nodal invasion, synchronous
metastasis development, tumour stage and worse 5- and 10-year survival of CRC patients. (3) PRR
expression in the centre and infiltrating front of primary tumours was similar (no intratumoural
heterogeneity) and was not associated with tumour budding. (4) PRR expression in metastases was
significantly lower than in primary tumours and was associated with worse survival of CRC patients.
(5) Plasmatic PRR levels did not vary between CRC patients and healthy controls and were not
correlated with CRC prognostic variables.
This study better supports the idea of PRR as a potential biomarker of CRC development and
progression. Taking into account that this disease is a major health problem in developed countries,
a better understanding of the role of PRR in colorectal carcinogenesis will be helpful for designing
effective diagnostic, prognostic and therapeutic tools for CRC.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/11/6/881/s1,
Table S1: Univariate analysis (Cox regression model) of clinical and pathological variables and PRR expression for
CRC patients’ 5-year overall survival prediction, Table S2: Univariate analysis (Cox regression model) of clinical
and pathological variables and PRR expression for CRC patients’ 10-year overall survival prediction, Table S3:
Multivariate analysis (Cox regression model) of clinical and pathological variables and PRR expression in the
centre of primary tumours and local and distant metastases for CRC patients’ 10-year overall survival prediction,
Table S4: Disease-free survival (DFS) of CRC patients according to PRR staining, Table S5: Association of PRR
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protein expression in primary tumours with tumour budding, Figure S1: 10-year overall survival of CRC patients
according to PRR staining. Figure S2: Immunohistochemical H&E staining for budding evaluation in primary
CRC. Figure S3: PRR knockdown in CRC cell lines for antibody’s specificity evaluation.
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